Related Articles
Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
Phase II study of vinorelbine with low dose prednisone in the treatment of hormone-refractory metastatic prostate cancer
Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer
Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer: Involvement of the intrinsic pathway of apoptosis
Oncoxin‑Viusid<sup>®</sup> may improve quality of life and survival in patients with hormone‑refractory prostate cancer undergoing onco‑specific treatments